The Journey of Clinical Manifestation Covid-19 After Favipiravir Treatment

DOI

10.2991/978-94-6463-112-8_69How to use a DOI?

Keywords

Covid-19; Clinical Manifestation; Treatment; Favipiravir

Abstract

The Clinical Manifestation Journey of Covid-19 is unpredictable, even after antiviral treatment. Favipiravir is one of the promising antivirals that is expected to stop the development of the disease so that it can eliminate the clinical symptoms of Covid-19. The question is to what extent the drug Favipiravir can do it, therefore this article's objective was to identify the clinical manifestation after Favipiravir treatment at Covid-19 subjects in 3 location studies in Indonesia. This study was a part of the main study related to the clinical trial of the efficacy and safety of Favipiravir for Subjects with moderate Covid-19. The study was conducted 2 times in 2020 and 2021 in 3 main hospitals with Covid-19 patients who came and were hospitalized as a population study. Age > 18 – 59 years old, with Covid-19 confirmation by PCR, voluntary and signed informed consent were inclusion criteria with pregnant women, and lactation and allergy were exclusion criteria. Favipiravir was given a maximum at day 14 plus another standard of care. A total of 66 cases were recruited in this study on day 1 but the number of samples continues to decrease as they are discharged from the hospital, with reduce 15,2% on day 7 and 57.6% on day 14. The result on Day 1 before taking Favipiravir showed 30% cases of fever, 75.8% cough, 10.7% cough, 22.7% sore throat, 45.5% fatigue, 45.5 headaches, 45.5% breathless, 4.5% diarrhea. The result at day 7 were 1.5%, 37.9%, 3.0%, 1.5%, 10.6%, 6.1%, 12.1%, 15.2%, sequentially. And the result at day 14 were 1.5%, 16.7%,0%,0,3%,1.5%, 6.1%, 0%, sequentially. The conclusion of the study was the changes in the clinical manifestations of Covid-19 remain unpredictable after the administration of the drug Favipiravir. In the future, an antiviral that can quickly eliminate the Covid-19 virus is needed so that clinical symptoms can be suppressed and make patients calm in dealing with them.

Copyright

© 2023 The Author(s)

Open Access

Open Access This chapter is licensed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.

Download article (PDF)

TY  - CONF
AU  - Armedy R. Hasugian
PY  - 2023
DA  - 2023/03/01
TI  - The Journey of Clinical Manifestation Covid-19 After Favipiravir Treatment
BT  - Proceedings of the 1st International Conference for Health Research – BRIN (ICHR 2022)
PB  - Atlantis Press
SP  - 767
EP  - 773
SN  - 2468-5739
UR  - https://doi.org/10.2991/978-94-6463-112-8_69
DO  - 10.2991/978-94-6463-112-8_69
ID  - Hasugian2023
ER  -